# A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

> **NCT02418819** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 103 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** PF-06412562 3mg BID
- **DRUG:** PF-06412562 9mg BID
- **DRUG:** PF-06412562 45mg BID
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02418819
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2019-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02418819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02418819, "A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02418819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*